Optimal dose-finding study of bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancer.

Background: Tri-weekly and weekly regimens of paclitaxel have been reported to be effective in unresectable advanced or recurrent gastric cancer. The present study was conducted to determine the optimal dose of bi-weekly paclitaxel and evaluate safety and antitumor effect.

Patients And Methods: The study included patients with a histologically confirmed diagnosis of advanced or recurrent gastric cancer.